Quick Answer
VitaNova Life Sciences Corp reported Net Income Loss of $850.7 thousand for the year ending 2025.
- VitaNova Life Sciences Corp showed an increase of +503.9% in Net Income Loss from 2024 to 2025.
- This data is from VitaNova Life Sciences Corp's annual report (Form 10-K), filed with the SEC on July 24, 2025.
- XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2017: -$7.2 thousand | Q3 2017: $9.6 thousand | Q4 2017: $5.8 thousand | Q1 2018: -$12.8 thousand | Q3 2018: -$15.8 thousand | Q4 2018: -$40.0 thousand | Q1 2019: -$36.7 thousand | Q3 2019: -$19.9 thousand | Q4 2019: -$19.5 thousand | Q1 2020: -$6.6 thousand | Q3 2020: -$11.2 thousand | Q4 2020: -$12.4 thousand | Q1 2021: -$2.9 thousand | Q3 2021: $142.6 thousand | Q4 2021: $15.0 thousand | Q1 2022: $8.9 thousand | Q3 2022: $2.1 thousand | Q4 2022: $2.6 thousand | Q1 2023: -$24.6 thousand | Q3 2023: -$24.2 thousand | Q4 2023: -$8.8 thousand | Q1 2024: $5.9 thousand | Q3 2024: -$55.2 thousand | Q4 2024: $32.6 thousand | Q1 2025: $73.0 thousand | Q3 2025: -$46.3 thousand | Q4 2025: $35.8 thousand | Q1 2026: -$44.4 thousand.
- Over the full 9 years of available data (2017 to 2025), VitaNova Life Sciences Corp's Net Income Loss has grown by 11,957.1%.
- Historical annual values: Fiscal year 2025: $850.7 thousand | Fiscal year 2024: $140.9 thousand | Fiscal year 2023: -$24.2 thousand | Fiscal year 2022: $139.7 thousand | Fiscal year 2021: -$52.1 thousand | Fiscal year 2020: -$72.3 thousand | Fiscal year 2019: -$106.2 thousand | Fiscal year 2018: -$1.6 thousand | Fiscal year 2017: -$7.2 thousand.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: